As mentioned above, methodological reliability was confirmed using positive (distilled water) and negative (0.9% saline) controls, yielding expected hemolysis values of 100% and 5%
BPC-157 + TB-500 is a blended peptide formulation combining two compounds frequently referenced in peptide research literature
If the advisory panel recommends, and the FDA agrees, that compounding eligibility should be determined primarily by market demand and political pressure rather than clinical evidence, the integrity of the drug approval system faces a meaningful structural challenge
Many clinics that offer this service only do so in a specific state or charge an absolute asinine price combined with shipping or seemed really shady
Accessed September 8, 2014
The most defensible rationale for oral BPC-157 is local action in the digestive tract itself